Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

unknown267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruiting

68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study

NCT05228106
unknownphase_2

Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

NCT05841992
unknownphase_2

68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

NCT04796467

Clinical Trials (3)

Showing 3 of 3 trials
NCT05228106

68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study

Recruiting
NCT05841992Phase 2

Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

Unknown
NCT04796467Phase 2

68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3